A Phase 2a, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
Latest Information Update: 17 May 2022
At a glance
- Drugs BGE 117 (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors BioAge Labs
Most Recent Events
- 29 Apr 2022 Planned End Date changed from 1 Feb 2022 to 1 Apr 2022.
- 29 Apr 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Apr 2022.
- 29 Apr 2022 Status changed from recruiting to withdrawn prior to enrolment.